Health Issues You May Face If You Have Hidradenitis Suppurativa

Health Issues You May Face If You Have Hidradenitis Suppurativa: An Ayurvedic Perspective

IntroductionHidradenitis Suppurativa (HS) is a chronic inflammatory skin condition marked by painful abscesses, nodules, and sinus tracts in areas with sweat glands, such as the underarms, groin, and buttocks (Alikhan et al., 2009; Sabin et al., 2019). While HS primarily affects the skin, its impact goes far beyond visible lesions. The condition is associated with a variety of physical, emotional, and systemic health complications, many of which can significantly diminish quality of life (Machado et al., 2019).

At EliteAyurveda, we take a holistic approach to managing HS and its related complications by focusing on balancing the body’s doshas (Kapha and Pitta) and eliminating toxins (Ama) that exacerbate the condition (Lad, 2002; Frawley, 2000). By addressing the root causes, Ayurveda not only alleviates symptoms but also prevents further complications (Sharma et al., 2007).

Issues You May Face If You Have Hidradenitis Suppurativa

Understanding the Complications Associated with HS

1. Chronic Pain and Discomfort

HS is characterized by painful, deep-seated nodules that can rupture and form tunnels under the skin, leading to persistent pain (Alikhan et al., 2009).

• Ayurvedic Insight: Pain is linked to aggravated Vata and Pitta doshas, causing inflammation and nerve irritation (Lad, 2002; Pole, 2013).
• Ayurvedic Solutions:
• Personalized herbal medications to calm Vata and Pitta imbalances (Frawley, 2000).

2. Recurrent Infections

The open sores and sinus tracts in HS make patients susceptible to bacterial and fungal infections, which can worsen inflammation and delay healing (Brook & Frazier, 1999).

• Impact: Repeated infections lead to increased antibiotic use, risking resistance or adverse effects.
• Ayurvedic Solutions:
• Detoxification therapies to cleanse the blood and lymphatic system (Sharma et al., 2007).
• Application of natural antiseptics and cooling herbal pastes to prevent infections (Pole, 2013).

3. Scarring and Restricted Mobility

Repeated flare-ups often result in thickened skin, scar tissue, and restricted mobility, especially in high-friction areas (Martorell et al., 2019).

• Impact: Scarring not only restricts movement but also affects self-esteem.
• Ayurvedic Solutions:
• Foods and herbs that nourish and heal the skin from within (Lad, 2002).

4. Emotional and Mental Health Challenges

HS often leads to anxiety, depression, and social withdrawal due to its chronic nature and visible scars (Machado et al., 2019). The stigma surrounding the condition exacerbates emotional distress.

• Ayurvedic Insight: Stress aggravates Vata, worsening inflammation and pain (Gupta & Gupta, 2003).
• Ayurvedic Solutions:
• Daily mindfulness practices, yoga, and meditation to calm the mind (Brown & Gerbarg, 2005).
• Herbal teas with adaptogenic herbs to reduce stress and anxiety (Frawley, 2000).

5. Lymphedema

Lymphedema, or localized swelling caused by poor lymphatic drainage, can occur in areas affected by HS (Alavi et al., 2015).

• Impact: Adds to pain and discomfort, further complicating mobility.
• Ayurvedic Solutions:
• Gentle massages with lymphatic-supportive oils to improve circulation (Lad, 2002).
• Diet modifications to include detoxifying and anti-inflammatory foods (Sharma et al., 2007).

6. Metabolic Disorders

HS is frequently linked to metabolic syndrome, including obesity, Type 2 diabetes, and insulin resistance (Egeberg et al., 2017).

• Impact: Complicates HS management and increases cardiovascular risk.
• Ayurvedic Solutions:
• A Kapha-pacifying diet with light, easily digestible foods (Pole, 2013).
• Herbal medications to regulate blood sugar and improve metabolism (Frawley, 2000).

7. Autoimmune Conditions

HS patients often suffer from overlapping autoimmune disorders like Crohn’s disease, lupus, and rheumatoid arthritis (Sabin et al., 2019).

• Impact: Increases systemic inflammation and treatment complexity.
• Ayurvedic Insight: Autoimmune disorders stem from doshic imbalances and immune dysregulation (Sharma et al., 2007).
• Ayurvedic Solutions:
• Strengthening immunity through personalized herbal treatments.
• Detoxification therapies to eliminate systemic toxins and reduce immune overactivity (Pole, 2013).

8. Hormonal Imbalances

Hormonal fluctuations can worsen HS symptoms, especially during menstruation, pregnancy, or menopause (Alikhan et al., 2009).

• Impact: Hormonal changes may trigger new lesions or intensify existing ones.
• Ayurvedic Solutions:
• Cooling and hormone-balancing foods like flaxseeds and aloe vera (Lad, 2002).
• Stress management to regulate cortisol levels and mitigate hormonal spikes (Brown & Gerbarg, 2005).

9. Gastrointestinal Disorders

Many HS patients experience digestive issues like bloating, irritable bowel syndrome (IBS), and constipation (Giamarellos-Bourboulis et al., 2016).

• Ayurvedic Insight: Weak digestion (Agni) and toxin buildup in the gut exacerbate systemic inflammation (Sharma et al., 2007).
• Ayurvedic Solutions:
• Digestive herbs like cumin, fennel, and ajwain to improve gut health (Frawley, 2000).
• Avoidance of heavy, processed foods that burden digestion (Pole, 2013).

10. Cardiovascular Risks

Chronic inflammation associated with HS can increase the risk of heart diseases, hypertension, and blood clots (Egeberg et al., 2017).

• Ayurvedic Insight: Long-term inflammation and Ama accumulation put strain on the cardiovascular system (Lad, 2002).
• Ayurvedic Solutions:
• Regular detoxification therapies to reduce systemic inflammation (Sharma et al., 2007).
• A diet rich in anti-inflammatory ingredients like turmeric, garlic, and leafy greens (Frawley, 2000).

How EliteAyurveda Manages HS and Its Complications

At EliteAyurveda, we go beyond treating visible symptoms to address the root causes of HS and its associated health issues. Our approach includes:

1. Comprehensive Detoxification:topical formulations (Phase E) to eliminate toxins and restore lymphatic health (Pandey & Chandola, 2013).
2. Personalized Herbal Medications:Tailored formulations to balance doshas, reduce inflammation, and prevent recurrence (Pole, 2013).
3. Dietary Guidance:Anti-inflammatory and Kapha-pacifying diets to improve digestion and reduce flare-ups (Frawley, 2000).
4. Lifestyle Modifications:Stress-reducing practices like yoga and pranayama to calm the mind and body (Brown & Gerbarg, 2005).Regular physical activity to improve mobility and lymphatic drainage (Lad, 2002).
5. Long-Term Support:Ongoing consultations and adjustments to ensure sustained remission and improved quality of life (Sharma et al., 2007).

From the Doctor’s Desk: Key Insights

• HS is Systemic: Addressing only the skin symptoms ignores the broader health implications of the condition (Sabin et al., 2019).
• Ayurveda Offers Holistic Solutions: By focusing on balancing the doshas, reducing Ama, and improving overall health, Ayurveda provides a sustainable path to managing HS and its complications (Lad, 2002; Pole, 2013).
• Empowerment Through Education: Understanding your condition is the first step toward managing it effectively.

Conclusion

Hidradenitis Suppurativa is a complex condition with far-reaching implications for overall health. From chronic pain and infections to mental health challenges and metabolic disorders, its impact goes beyond the surface (Machado et al., 2019). Ayurveda offers a holistic, patient-centered approach to managing HS and its complications, helping patients regain control of their health and improve their quality of life.

At EliteAyurveda, we are dedicated to empowering our patients with personalized Ayurvedic care that addresses the root causes of their conditions.

📞 Contact us at +91 8884722246🌐 Visit our website: www.eliteayurveda.com

Related-

Know More About Ayurveda Treatment For Hidradenitis Suppurativa.

GET IN TOUCH

Schedule a Visit

Contact us

References

1.Nguyen T.V., Damiani G., Orenstein L.A., Hamzavi I., Jemec G. Hidradenitis suppurativa: An update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J. Eur. Acad. Dermatol. Venereol. 2021;35:50–61. doi: 10.1111/jdv.16677. [DOI] [PubMed] [Google Scholar]

2.Matusiak L., Kaszuba A., Krasowska D., Placek W., Szepietowski J. Epidemiology of hidradenitis suppurativa in Poland against the background of world data. Dermatol. Rev. 2017;104:377–384. doi: 10.5114/dr.2017.69945. [DOI] [Google Scholar]

3.Zouboulis C.C., del Marmol V., Mrowietz U., Prens E.P., Tzellos T., Jemec G.B. Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation. Dermatology. 2015;231:184–190. doi: 10.1159/000431175. [DOI] [PubMed] [Google Scholar]

4.Jfri A., Nassim D., O’brien E., Gulliver W., Nikolakis G., Zouboulis C.C. Prevalence of Hidradenitis Suppurativa. JAMA Dermatol. 2021;157:924–931. doi: 10.1001/jamadermatol.2021.1677. [DOI] [PMC free article] [PubMed] [Google Scholar]

5.Condamina M., Penso L., Tran V.-T., Hotz C., Guillem P., Villani A.P., Perrot P., Bru M.-F., Jacquet E., Nassif A., et al. Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts. Dermatology. 2021;237:748–758. doi: 10.1159/000513447. [DOI] [PubMed] [Google Scholar]

6.Abu Rached N., Gambichler T., Ocker L., Dietrich J., Quast D., Sieger C., Seifert C., Scheel C., Bechara F.G. Screening for Diabetes Mellitus in Patients with Hidradenitis Suppurativa—A Monocentric Study in Germany. Int. J. Mol. Sci. 2023;24:6596. doi: 10.3390/ijms24076596. [DOI] [PMC free article] [PubMed] [Google Scholar]

7.Canoui-Poitrine F., Le Thuaut A., Revuz J.E., Viallette C., Gabison G., Poli F., Pouget F., Wolkenstein P., Bastuji-Garin S. Identification of three hidradenitis suppurativa phenotypes: Latent class analysis of a cross-sectional study. J. Investig. Dermatol. 2013;133:1506–1511. doi: 10.1038/jid.2012.472. [DOI] [PubMed] [Google Scholar]

8.Matusiak L., Bieniek A. Inverted acne treated surgically with innovative techniques to reduce the resulting cavities—A case report. Dermatol. Rev. 2011;98:390–394. [Google Scholar]

9.Kiss N., Plázár D., Lőrincz K., Bánvőlgyi A., Valent S., Wikonkál N. Gynecological aspects of hidradenitis suppurativa. Orv. Hetil. 2019;160:291–299. doi: 10.1556/650.2019.31319. [DOI] [PubMed] [Google Scholar]

10.Sabat R., Jemec G.B.E., Mayusiak Ł., Kimball A.B., Prenas E. Hidradenitis suppurativa. Nat. Rev. Dis. Primers. 2020;12:18. doi: 10.1038/s41572-020-0149-1. [DOI] [PubMed] [Google Scholar]

11.Preda-Naumescu A., Ahmed H.N., Mayo T.T., Yusuf N. Hidradenitis suppurativa: Pathogenesis, clinical presentation, epidemiology, and comorbid associations. Int. J. Dermatol. 2021;60:e449–e458. doi: 10.1111/ijd.15579. [DOI] [PubMed] [Google Scholar]

12.Daoud M., Suppa M., Benhadou F., Daxhelet M., Njimi H., White J., Jemec G., Del Marmol V. Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data. Front. Med. 2023;10:1145152. doi: 10.3389/fmed.2023.1145152. [DOI] [PMC free article] [PubMed] [Google Scholar]

13.Zouboulis C.C., Tzellos T., Kyrgidis A., Jemec G.B.E., Bechara F.G. Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. Br. J. Dermatol. 2017;177:1401–1409. doi: 10.1111/bjd.15748. [DOI] [PubMed] [Google Scholar]

14.Zouboulis C., Matusiak L., Jemec G., Szepietowski J., Álvarez-Chinchilla P., Asoskova A., Bonnekoh H., Brattoli G., Cetinarslan T., Dawicka J., et al. Inter-rater and intrarater agreement and reliability in clinical staging of hidradenitis suppurativa/acne inversa. Br. J. Dermatol. 2019;181:852–854. doi: 10.1111/bjd.17982. [DOI] [PubMed] [Google Scholar]

15.Wortsman X., Moreno C., Soto R., Arellano J., Pezo C., Wortsman J. Ultrasound In-Depth Characterization and Staging of Hidradenitis Suppurativa. Dermatol. Surg. 2013;39:1835–1842. doi: 10.1111/dsu.12329. [DOI] [PubMed] [Google Scholar]

16.Nazzaro G., Passoni E., Guanziroli E., Casazza G., Muratori S., Barbareschi M., Veraldi S., Marzano A.V. Comparison of clinical and sonographic scores in a cohort of 140 patients with hidradenitis suppurativa from an Italian referral centre: A retrospective observational study. Eur. J. Dermatol. 2018;28:845–847. doi: 10.1684/ejd.2018.3430. [DOI] [PubMed] [Google Scholar]

17.Oranges T., Vitali S., Benincasa B., Izzetti R., Lencioni R., Caramella D., Romanelli M., Dini V. Advanced evaluation of HS with ultra-high frequency ultrasound: A promising tool for the diagnosis and monitoring of disease progression. Skin Res. Technol. 2020;26:513–519. doi: 10.1111/srt.12823. [DOI] [PubMed] [Google Scholar]

18.Jorgensen A.H.R., Thomsen S.F., Ring H.C. Clinical phenotypes of hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 2019;33:e111–e112. doi: 10.1111/jdv.15276. [DOI] [PubMed] [Google Scholar]

19.Mintoff D., Pace N.P., Borg I. NCSTN In-Frame Deletion in Maltese Patients With Hidradenitis Suppurativa. JAMA Dermatol. 2023;26:e232227. doi: 10.1001/jamadermatol.2023.2227. [DOI] [PMC free article] [PubMed] [Google Scholar]

20.Collier E.K., Parvataneni R.K., Lowes M.A., Naik H.B., Okun M., Shi V.Y., Hsiao J.L. Diagnosis and management of hidradenitis suppurativa in women. Am. J. Obstet. Gynecol. 2021;224:54–61. doi: 10.1016/j.ajog.2020.09.036. [DOI] [PMC free article] [PubMed] [Google Scholar]

21.López-Llunell C., Romaní J., Garbayo-Salmons P., Agut-Busquet E. Vulvar hidradenitis suppurativa: Clinical cross-sectional study of 25 patients. J. Dermatol. 2021;48:457–463. doi: 10.1111/1346-8138.15728. [DOI] [PubMed] [Google Scholar]

22.Fabbrocini G., Ruocco E., De Vita V., Monfrecola G. Squamous cell carcinoma arising in longstanding hidradenitis suppurativa: An overlooked facet of the immunocompromised district. Clin. Dermatol. 2016;35:225–227. doi: 10.1016/j.clindermatol.2016.10.019. [DOI] [PubMed] [Google Scholar]

23.Sevray M., Dupré P.-F., Le Flahec G., Trimaille A., Misery L., Brenaut E. Vulvar squamous cell carcinoma complicates hidradenitis suppurativa in a young woman. JAAD Case Rep. 2019;5:999–1001. doi: 10.1016/j.jdcr.2019.08.025. [DOI] [PMC free article] [PubMed] [Google Scholar]

24.Vergeldt T., Driessen R., Bulten J., Nijhuis T., de Hullu J. Vulvar cancer in hidradenitis suppurativa. Gynecol. Oncol. Rep. 2022;39:100929. doi: 10.1016/j.gore.2022.100929. [DOI] [PMC free article] [PubMed] [Google Scholar]

25.Scheinfeld N. A case of a patient with stage III familial hidradenitis suppurativa treated with 3 courses of infliximab and died of metastatic squamous cell carcinoma. Dermatol. Online J. 2014:20. doi: 10.5070/D3203021764. [DOI] [PubMed] [Google Scholar]

26.Cuenca-Barrales C., Montero-Vilchez T., Salvador-Rodríguez L., Sánchez-Díaz M., Arias-Santiago S., Molina-Leyva A. Implications of Hidradenitis Suppurativa Phenotypes in Cardiovascular Risk and Treatment Decisions: A Retrospective Cohort Study. Dermatology. 2021;237:727–732. doi: 10.1159/000513044. [DOI] [PubMed] [Google Scholar]

27.Al Ghamdi D.S. Miscarriage as a Complication of Hidradenitis Suppurativa of the Vulva. Int. J. Womens Health. 2020;29:939–942. doi: 10.2147/IJWH.S268050. [DOI] [PMC free article] [PubMed] [Google Scholar]

28.Karagiannidis I., Nikolakis G., Zouboulis C.C. Endocrinologic Aspects of Hidradenitis Suppurativa. Dermatol. Clin. 2016;34:45–49. doi: 10.1016/j.det.2015.08.005. [DOI] [PubMed] [Google Scholar]

29.Van Der Zee H.H., Laman J.D., Boer J., Prens E.J. Hidradenitis suppurativa: Viewpoint on clinical phenotyping, pathogenesis, and novel treatments. Exp. Dermatol. 2012;21:735–739. doi: 10.1111/j.1600-0625.2012.01552.x. [DOI] [PubMed] [Google Scholar]

30.Nazzaro G., Zerboni R., Passoni E., Barbareschi M., Marzano A.V., Muratori S., Veraldi S. High-frequency ultrasound in hidradenitis suppurativa as rationale for permanent hair laser removal. Skin Res. Technol. 2019;25:587–588. doi: 10.1111/srt.12671. [DOI] [PubMed] [Google Scholar]

31.Vossen A.R.J.V., van der Zee H.H., Prens E.P. Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. Front. Immunol. 2018;9:2965. doi: 10.3389/fimmu.2018.02965. [DOI] [PMC free article] [PubMed] [Google Scholar]